Deciphering epistatic genetic regulation of cardiac hypertrophy

Competing Interest Statement

E.A.A. is a founder of Personalis, Deepcell, Svexa, Candela, Saturnus Bio, and Parameter Health; an advisor to SequenceBio, Foresite Labs, Pacific Biosciences, and Versant Ventures; a non-executive director for AstraZeneca and Svexa; a stockholder in Pacific Biosciences and AstraZeneca; and has received in-kind collaborative support from Illumina, Pacific Biosciences, Oxford Nanopore, Cache, and Cellsonics. V.N.P. is an SAB member for and receives research support from BioMarin, Inc., an SAB member for Lexeo Therapeutics, and a consultant for Constantiam Biosciences and viz.ai. C.S.W. is a consultant for AiRNA Bio and Avidity Biosciences. While these companies may have interests in genomics or cardiovascular health, they had no direct role in the design, data presentation, analysis, or interpretation of this study. The remaining authors declare no competing interest.

Funding Statement

This work was supported by the Chan Zuckerberg Biohub - San Francisco through the Intercampus Research Awards (2019 - 2022) (R.A., J.R.P., J.B.B., A.J.B., E.A.A., B.Y.); the National Institutes of Health (NIH) through grant numbers 1R01HL144843 (E.A.A.), R01GM152718 (B.Y.), K08HL143185 (V.N.P.), R01HL105993 (W.H.W.T., K.B.M., T.P.C., E.A.A.), F32HL160067 (C.S.W.), K08HL167699 (C.S.W.), and L30HL159413 (C.S.W.); the American Heart Association (AHA) through grant numbers 23POST1023278 (Q.W.) and 23CDA1042900 (C.S.W.); the National Science Foundation (NSF) through grants DMS-1613002 (B.Y.), IIS 1741340 (B.Y.), and the Graduate Research Fellowship Program DGE-2146752 (T.M.T); and a Weill Neurohub grant (B.Y.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The use of human subjects (IRB - 4237) and human-derived induced pluripotent stem cells (SCRO - 568) in this study has been approved by the Stanford Research Compliance Office. The UK Biobank received ethical approval from the North West - Haydock Research Ethics Committee (21/NW/0157).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes